Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Shares Outstanding (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Shares Outstanding for 12 consecutive years, with $51.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 3.23% to $51.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.1 million through Dec 2025, up 3.23% year-over-year, with the annual reading at $51.1 million for FY2025, 3.23% up from the prior year.
  • Shares Outstanding for Q4 2025 was $51.1 million at Theravance Biopharma, up from $50.7 million in the prior quarter.
  • The five-year high for Shares Outstanding was $76.4 million in Q2 2022, with the low at $48.1 million in Q4 2023.
  • Average Shares Outstanding over 5 years is $59.2 million, with a median of $52.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 16.66% in 2022, then fell 29.74% in 2023.
  • Over 5 years, Shares Outstanding stood at $74.4 million in 2021, then dropped by 12.37% to $65.2 million in 2022, then fell by 26.27% to $48.1 million in 2023, then rose by 2.87% to $49.5 million in 2024, then rose by 3.23% to $51.1 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $51.1 million, $50.7 million, and $50.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.